Company / R&D Expense
Arbutus Biopharma Corp R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$25.2M
FY2025
5-year range
$25.2M / $84.4M
FY2021-FY2025
Trend
-53.3%
vs FY2024
Sector context
#194 of 210
Health Care
What the data says
Among 210 Health Care companies, Arbutus Biopharma Corp is in the bottom 8% for r&d expense. R&D Expense has declined for 3 consecutive years, from $84M in FY2022 to $25M in FY2025.
Based on SEC 10-K filings.
$25M in FY2025 with a 5-year CAGR of -15.2%.
Declined from $74M to $25M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -33.1%
- 5-Year CAGR
- -15.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 210This company $25.2M Sector average $644.1M
▼
-96.1% below sector average
Key checks
Key Insights
- Arbutus Biopharma Corp's r&d expense has declined for 3 consecutive years.
- 5-year CAGR of -15.2%, indicating a declining trend.
- In FY2025, r&d expense decreased 53.3% year-over-year.
- Ranks #194 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $25.2M | -53.3% |
| FY2024 | $54.0M | -26.7% |
| FY2023 | $73.7M | -12.7% |
| FY2022 | $84.4M | +28.9% |
| FY2021 | $65.5M | +13.7% |
| FY2020 | $57.6M | -0.6% |
| FY2019 | $57.9M | -7.6% |
| FY2018 | $62.7M | +0.0% |
| FY2017 | $62.7M | +2.3% |
| FY2016 | $61.3M | +18.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026